Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus
Objective: Plasmacytoid dendritic cells (pDCs) are a major source of Type-I Interferon (IFN-I), a key driver in cutaneous lupus erythematosus (CLE). Currently evaluated in Phase II clinical trial, 24F4A (BIIB059) is an antibody targeting BDCA2, an inhibitory receptor expressed on pDCs. Given that Hy...
Main Authors: | Agnes Gardet, Alex Pellerin, Christie-Ann McCarl, Rohan Diwanji, Wenting Wang, Douglas Donaldson, Nathalie Franchimont, Victoria P. Werth, Dania Rabah |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00275/full |
Similar Items
-
Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus
by: Noël Zahr, et al.
Published: (2021-03-01) -
New onset bullous lupus erythematosus in a systemic lupus erythematosus patient after initiation of hydroxychloroquin
by: Chanchal Gera, et al.
Published: (2014-01-01) -
Highly selective inhibition of Bruton’s tyrosine kinase attenuates skin and brain disease in murine lupus
by: Samantha A. Chalmers, et al.
Published: (2018-01-01) -
Evaluation of the mortality in systemic Lupus erythematosis (SLE): Analysis of 2021 patients
by: Gharibdoost F, et al.
Published: (2003-03-01) -
Evaluation of the mortality in systemic Lupus erythematosis (SLE): Analysis of 2021 patients
by: Gharibdoost F, et al.
Published: (2003-05-01)